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MitoNEET (gene cisd1) is a mitochondrial outer membrane [2Fe-2S] protein and is a potential
drug target in several metabolic diseases. Previous studies have demonstrated that mitoNEET
functions as a redox-active and pH-sensing protein that regulates mitochondrial metabolism,
although the structural basis of the potential drug binding site(s) remains elusive. Here we
report the crystal structure of the soluble domain of human mitoNEET with a sulfonamide
ligand, furosemide. Exploration of the high-resolution crystal structure is used to design
mitoNEET binding molecules in a pilot study of molecular probes for use in future develop-
ment of mitochondrial targeted therapies for a wide variety of metabolic diseases, including
obesity, diabetes and neurodegenerative diseases such as Alzheimer’s and Parkinson’s
disease.
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M itoNEET (gene cisd1) was identified in 2004 as the firstexample of a mitochondrial outer-membrane iron–sulfurprotein, with the cluster binding domain facing the cyto-
solic side1. This protein was initially discovered as the unintended
target for the anti-diabetic peroxisome proliferator-activated receptor
gamma (PPAR-γ) agonist pioglitazone, as many of the beneficial
effects of pioglitazone, a thiazolidinedione (TZD), could not be
explained by PPAR-γ activity alone1. MitoNEET assembles as a
homodimer, with each subunit containing a rather unusual [2Fe–2S]-
type iron–sulfur cluster coordinated by His87 and three cysteine
residues2. The amino acids coordinating the [2Fe–2S] cluster form a
signature CDGSH domain common to all members of the CISD-
gene family. Bioinformatics analysis has shown that the CISD-gene
family is highly conserved across a variety of species, including
mammals, Caenorhabditis elegans, plants as well as thermophilic
archaea and bacteria, with a high degree of structural homology
(particularly around the cluster binding domain) among the different
phyla3. To date three CISD proteins have been crystalized, including
human mitoNEET (gene cisd1), miner1/NAF-1 (gene cisd2), and
miner2/miNT (gene cisd3)4,5.
MitoNEET plays an important role in mitochondrial function and
metabolism6–10. Overexpression of mitoNEET in the adipose tissue
of ob/ob mice led to a significant reduction in inflammation and
oxidative stress as compared to the control mice7. In addition,
overexpression of mitoNEET in cardiomyocytes was protective
against oxidative stress as induced by hydrogen peroxide11,12. In
contrast, when mitoNEET was knocked out of mice the resulting
phenotype was characterized by a loss of dopamine neurotransmitter
levels from the striatum and Parkinson’s disease type motor defi-
cits13. Although the detailed mechanistic aspects underlying these
physiological functions remain elusive, current understanding of
mitoNEET correlates to the crucial role of the redox-active [2Fe–2S]
clusters, possibly serving as an outer-membrane redox-sensor and pH
sensor for mitochondrial function and/or a potential source of the
iron–sulfur cluster transfer to cytosol in response to the redox states
in the cells8,9.
Despite the fact that mitoNEET was described relatively
recently, numerous crystal structures have been reported for both
the wild-type and mutants of the soluble portions (PDB codes
2QH7, 2QDO, 2R13, 3EW0, 3REE, 3LPQ, 4EZF, 4F1E, 4F28, and
4F2C). However, none of these crystal structures includes a
bound ligand that has drug-like activity. Here, we describe the
crystal structure of a mitoNEET–ligand complex with furosemide.
This structure can be used to gain structural insights into mito-
NEET binding to ligands, as well as be used in structure-based
drug discovery (SBDD) studies.
Results
Co-crystallization study. Based on the published literature, mito-
NEET represents a potential drug target for the development of
compounds to treat a variety of metabolic diseases6,7,14. Unfortu-
nately, no crystal structure has been solved with a ligand bound to the
protein for use in SBDD studies. Here, we present the first crystal
structure at 1.95 Å resolution of human mitoNEET with a bound
benzoic-sulfonamide-furan ligand, furosemide. Our previous
approaches to screening condition for soaking with the prototypical
mitoNEET ligands TZDs such as pioglitazone and NL-1 did not yield
any crystals, mainly due to solubility problems of the TZD-
containing compounds. This led us to explore an alternative
approach, which was to find a soluble mitoNEET ligand which is
suitable for co-crystallization with the human mitoNEET protein. We
theorized from earlier crystal structure of mitoNEET that the LYS55
and HIS87 would be of importance, and the free carboxylic group of
furosemide would likely interact via hydrogen bonding15. We have
previously reported that furosemide binds to mitoNEET with
moderate affinity (IC50 ~40 µM)16, using a recombinant mitoNEET
with a mitoNEET-His protein, as opposed to the His-SUMO protein
we used here for crystallography. We focused on furosemide in this
study due to its appropriateness for the X-ray diffraction studies, due
to its favorable solubility profile, as opposed to the glitazones where
solubility in the crystallization mother liquor is limiting. In addition,
we did not observe any aggregate formation with furosemide in
solution using dynamic light scattering (DLS), which could interfere
with the crystallography studies (Supplementary Fig. 1).
The crystal structure of furosemide bound to mitoNEET is
shown in Fig. 1, with the crystal data (6DE9.pdb) given in
Table 1. In the refined structure, furosemide is bound on the face
close to the [2Fe–2S] cluster in each monomer, which are critical
for the biological function of mitoNEET (Fig. 1a). The bound
ligand was supported by strong density after MR-SAD phasing
and refinement, and was further confirmed by simulated
annealing OMIT map analysis (Fig. 1b, c). The furosemide
carboxylic groups are in reach of the [2Fe–2S] coordinating
His87 side chain for possible hydrogen bonding with His87Nε. In
addition, the furan ring of furosemide can be modeled such that
the oxygen is pointed toward Sγ of the Cys83 ligand, although the
limited resolution of the refined electron density map cannot
discriminate the precise orientation of the furosemide furan ring
in the present study. The furosemide-binding site observed in the
crystal structure corresponds to previously hypothesized binding
pocket, from molecular docking studies performed with the
anticancer drug MAD-28 corroborating our finding17. In
addition, the pocket identified by furosemide is suggested to
correspond to a possible binding site for pioglitazone, for which
nuclear magnetic resonance studies indicated causes perturba-
tions in the overall structure and to be close to a Trp or Phe
residues, although the exact residues still need to be determined2.
In accordance, the Phe82 side chain is within a 5 Å distance from
the furosemide furan ring in the refined structure, which could
suggest that this is the same binding site that pioglitazone
occupies. We previously identified other possible binding pockets
from docking studies, which was located near the α-helix of
mitoNEET, and predicted this to be the primary site for
resveratrol-3-sulfate and pioglitazone binding15,18. Considering
also the previous report that pioglitazone inhibits cluster release
from mitoNEET under oxidative stress19, it seems likely that the
compounds binding in the furosemide pocket would stabilize the
ligation environment of the [2Fe–2S] cluster. The observation
that mutation of HIS87 to CYS has a cluster stabilizing effect and
caused a significant shift in the reduction potential is also
consistent with this model20. Regardless of whether the main
function of mitoNEET in the cell is as a redox sensor, iron
chaperone, or as an electron-transport protein, binding of a
ligand so near to the cluster is likely to have a significant impact
on cellular energetics.
Ligand development. As proof of principle, we developed a small
pilot set of compounds to validate that the interaction between
furosemide and mitoNEET, both in the binding assay and the
crystal structure. This was in part to ensure that the interaction
we observe for furosemide was not due to nonspecific interaction
with the [3H]rosiglitazone. We developed an ELISA capture assay
using a streptavidin capture plate and a biotin–furosemide probe.
As can be seen in Fig. 2a, mitoNEET recombinant protein is dose-
dependently captured by the probe and is detectable by a primary
antibody against mitoNEET, suggesting that the interaction we
have observed from our binding assays were due to a binding
interaction. Furthermore, we used the probe to isolate recombi-
nant mitoNEET from a sample of cell lysate (Fig. 2b). In the
presence of furosemide, we were able to show dose-dependently
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the reduction of mitoNEET captured in the pull-down assay. The
most prominent reduction in binding was seen with the ~25 kDa
band, in contrast to the ~12 kDa. Lastly, we used an orthogonal
assay to assess interaction between mitoNEET and furosemide.
Surface plasmon resonance (SPR) indicated that the association
rate constant Kon was 5.6 × 102 M−1 s−1, a dissociation rate
constant Koff of 3.0 × 10−2 M−1 s−1 and the equilibrium dis-
sociation constant Kd is 53.5 μM (Supplementary Fig. 2).
The discovery that we could use furosemide as a probe for
crystallography of mitoNEET, led us to synthesize a series of
derivatives to validate the use of our crystal in molecular probe
development, and for exploring structure–activity relationships
of these sulfonamide compounds. As proof of principle, we
synthesized 11 furosemide analogs (Fig. 3 which were prepared
from the commercially available sulfonamide 1 by microwave
synthesis (see Supplementary methods)). Before we synthesized
the compounds, we docked them into the furosemide-binding
site, and found them to occupy the binding pocket supporting
synthesis initiation. The displacement IC50s of [3H]rosiglita-
zone with the human recombinant mitoNEET for these
compounds are shown in Table 2 and Fig. 4 showing
representative binding curves. We found that the extension of
the alkyl chain increased the affinity, with an optimal length of
between five and eight carbons within the current set of
compounds tested. The importance of an aliphatic or aromatic
side chain was verified from the use of compound 1, which does
not have either of these substitutions. Similarly, based on this
observation, we found that arachidonic acid showed similar
binding characteristics, sharing both the ring type structure of
the TZD warhead and the lipophilic tail21. We found that
inclusion of ring structures, specifically aromatic in nature,
would improve the affinity of compounds. For example, the
exclusion of a ring in 2a led to a dramatic decrease in ability to
displace [3H[rosiglitazone from observed IC50 of 22 μM of
furosemide to 81 μM for 2a.
A general pharmacophore model is shown in Fig. 4. Using the
crystal structure of furosemide with mitoNEET, we docked a
series of compounds, (furosemide, TT01001, NL-1, and rosigli-
tazone) into the furosemide-binding pocket/site, and developed a
preliminary pharmacophore model for the pocket. In this case,


















Fig. 1 Crystal structure of human mitoNEET in complex with the bound ligand furosemide. a MitoNEET dimer shown with the [2Fe–2S] cluster and
coordinating amino acids. Furosemide is shown in atom colors. b 2Fo–Fc map (contoured at 1σ) showing bound ligand electron density. c Fo–Fc OMIT map
(contoured at 2.5σ) further validates the position of the bound furosemide ligand. d Structure of furosemide




Space group I 41 2 2
Cell dimensions
a, b, c (Å) 58.83, 58.83, 176.75
α, β, γ (°) 90, 90, 90
Resolution (Å) 30.30–1.95 (2.02–1.95)
Rsym or Rmerge 0.0353 (0.2533)
I /σI 40.90 (2.24)
Completeness (%) 99.92 (100.00)
Redundancy 21.8 (21.1)
Refinement
Resolution (Å) 30.30–1.95 (2.02–1.95)
No. of reflections 11791 (1146)
Rwork/Rfree 19.97/22.1









Bond lengths (Å) 0.010
Bond angles (°) 1.75
Values in parentheses are for highest-resolution shell.
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the appearance of two hydrophobic/aromatic centers, two
hydrogen bond acceptors, and one hydrogen bond acceptor/
donor, underpinning future studies into interactions with LYS55
and HIS87 similar to interactions suggested with other com-
pounds such as the anticancer compound MAD-2817.
Previous studies have shown that mitoNEET loses the
iron–sulfur [2Fe-2S] clusters in low pH22. To validate that the
interaction between furosemide and mitoNEET in the crystal is
not due to nonspecific interactions, we tested furosemide’s ability
to slow down the release of the clusters form mitoNEET. As seen
in Fig. 5, furosemide is able to reduce cluster loss at pH
6.5 suggesting the interaction with mitoNEET to be specific to the
cluster region.
Furosemide was chosen for this crystal structure study due to
speculated interaction to key residues9, as well as previous
literature which indicated a possible mitochondrial interaction23.
Since we found that furosemide binds to mitoNEET, albeit in the
micromolar range, and that mitoNEET is thought to regulate
mitochondrial bioenergetics2,17,24, we evaluated the new deriva-
tives for possible mitochondrial activity. To evaluate the new
compounds for pharmacological activity, we tested their ability to
affect mitochondrial bioenergetics (Fig. 6). N2A cells were used to
evaluate the activity, since most of our previous work with
mitoNEET centered on neurodegenerative diseases, including
Parkinson’s disease13. As control compounds, we used furose-
mide and the mitoNEET ligand NL-1. We found that the
compounds 2l (mitoNEET IC50= 20.7 μM) and 2f (mitoNEET
IC50= 6.2 μM) were able to increase both basal respiration
(oxygen consumption rate), and maximal respiration in each case,
similar to NL-1 and furosemide. The spare respiratory capacity
was also increased, with a commiserate increase in ATP-linked
oxygen consumption. As signs of health, the proton leak and
spare respiratory capacity were not changed with the addition of
the compounds, although furosemide trended to increase proton
leak. In support of these findings in cell culture, we isolated fresh
brain mitochondria from mice. Evaluation of the oxidative
















2a n = 2
2b n = 3
2c n = 4
2d n = 5
1
2e n = 6







2l X = H




2p X = S
Furosemide X = O
2a-p
2n X = F
Fig. 3 Microwave-assisted synthesis of furosemide analogs. Eleven
compounds 2a–p were prepared from the commercially available
sulfonamide 1 by microwave synthesis and tested for mitoNEET binding and
respiration studies
Table 2 Displacement of [3H]rosiglitazone by sulfonamide
compounds with recombinant human mitoNEET
Compounds IC50 (μM) ±std error clogPa
Furosemide 29.26 ± 0.97 1.90
1 1021.00 ± 0.96 1.11
2a 81.43 ± 0.92 2.33
2b 42.56 ± 1.03 2.86
2c 54.26 ± 0.92 3.39
2d 9.12 ± 1.04 3.92
2e 19.82 ± 0.90 4.45
2f 6.24 ± 0.88 4.98
2k 31.16 ± 1.02 3.31
2l 20.79 ± 1.01 2.72
2n 8.82 ± 1.00 2.87
2p 12.38 ± 1.23 2.37
Arachidonic acid 2.93 ± 1.06 6.3
aCalculate using Chemdraw 16.0.1.4



























Fig. 2 Interaction with furosemide and mitoNEET. a To evaluate an indirect binding effect of the interaction of furosemide with mitoNEET, a ELISA
biotin–streptavidin capture assay shows that the furosemide–biotin probe is able to capture mitoNEET and be detected with a primary antibody; b the
addition of furosemide (0–100 μM) is able to reduce the amount of mitoNEET captured from a N2A cell lysate by the furosemide-probe attached to
streptavidin breads. Treatment: mitoNEET (mN); vehicle only (VC). RAU relative absorbance units
ARTICLE COMMUNICATIONS CHEMISTRY | https://doi.org/10.1038/s42004-019-0172-x
4 COMMUNICATIONS CHEMISTRY |            (2019) 2:77 | https://doi.org/10.1038/s42004-019-0172-x | www.nature.com/commschem
with mitochondria (Fig. 7), specifically we noticed an increase in
complex I and III activity. Similar effects were seen when we
tested two other compound, 2f and 2l. Complex IV and ATP
synthase were mildly inhibited by the compounds at the
concentration tested. DLS follow-up studies suggested that the
compounds did not form aggregates in the buffers, which could
lead to false positives (Supplementary Fig. 1)25. The current
interpretation of the mitochondrial data in the presence of
furosemide does not exclude that possibility that the effects could
be unrelated to mitoNEET biochemistry. Future studies will be





























Fig. 4 X-ray crystal of mitoNEET with furosemide used to develop novel derivatives. a Docked poses of compounds, 2f, 2l, and 2n to illustrate the ability to
design compound to interact with HIS87, LYS55, and LYS68; b, c Pharmacophore query for the binding pocket from docking studies. The furosemide bound






























Fig. 5 Iron–sulfur cluster release from mitoNEET. Furosemide is able to slow down cluster release comparing a pH 8 to b pH 6.5 when measured at 458 nm.
Compounds were tested at 20 μM final concentration each. Vehicle control is mitoNEET (mN) with DMSO
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needed to evaluate the full scope of biochemical activity of
furosemide at the mitochondrial level, as well as its phenotypical
role in disease management.
Discussion
MitoNEET is a mitochondrial protein with redox and pH sensor
activity, which has been of interest toward designing compounds
to modulate bioenergetics of mitochondria2,17,22,24. Of late no
structure has been published which contains mitoNEET protein
with a small organic compound bound as a complex, which has
hampered progress in designing mitoNEET ligands. In this study,
our goal was to identify a compound that could be used to achieve
a co-crystal structure with mitoNEET, as the glitazones tended to
precipitate out of solution failing to co-crystalize. We present a
mitoNEET crystal structure in complex with a benzoic-
sulfonamide-furan drug bound for use in future drug develop-
ment studies. Our crystal structure was used to design com-
pounds that could give insight into structure–activity
relationships of the scaffold. The primary binding site identified
correlates with the redox-active [2Fe–2S] cluster ligation site, and
binding to the HIS87 and LYS55 may inhibit its redox function
and/or possible cluster release/breakdown at the cytoplasmic
side2,17,24. With the current results, discovery programs can be
focused on developing probes to study the pharmacology of
mitoNEET and possibly develop novel compounds as first-in-
class to treat mitochondrial dysfunction such as Parkinson’s
disease26.
Methods
Chemical synthesis. See Supplementary methods.
Protein expression and purification. Plasmid pET11a-His-SUMO-mitoNEET was
constructed from a synthetic gene block (IDT) cloned between Nde I and Bam HI.
MitoNEET recombinant protein for crystallography was expressed as a fusion with





Protein expression was performed in Rosetta 2 (DE3) cells. Cells were grown in
TB both by autoinduction at 25 °C overnight, harvested at 5000 × g for 15 min, and
resuspended in lysis buffer (20 mM Tris-HCl (pH 8.5), 0.3 M NaCl, 10 mM
imidazole). Cells were lysed by sonication, and the lysates were cleared at 15,000×g
for 15 min. Cleared lysate was bound to Ni-NTA resin (Gold Biotechnology),
washed with lysis buffer containing 20 mM imidazole, and eluted with lysis buffer
containing 300 mM imidazole. Purified mitoNEET was desalted over a PD-10
column with 10 mM Tris-HCl (pH 8.0), 100 mM NaCl. The purification tag was
removed by digestion with His-tagged SUMO protease at 4 °C overnight. The
cleaved tag and His-SUMO protease was removed by a second binding to Ni-NTA
resin, followed by size exclusion chromatography. The His tag was followed by a
flexible Ser/Gly linker fused to a SUMO motif. After expression SUMO protease
(specific cleavage after QIGG) was used to remove the fusion purification tag. After
these steps, the final amino acid primary sequence is as follows:
TKRFYVKDHRNKAMINLHIQKDNPKIVHAFDMEDLGDKAVYCRCWRSK
KFPFCDGAHTKHNEETGDNVGPLIIKKKET.
Crystallization and refinement of mitoNEET-furosemide. Purified mitoNEET
protein (20 mg/ml) mixed with an equal molar concentration of furosemide was
screened by sitting drop vapor diffusion against Index screen (Hampton
Research). Red crystals formed in under a week in several conditions. Final data
collection was performed using crystals grown by sitting drop vapor diffusion by
mixing a 1:1 ratio of protein with 60% v/v Tacsimate pH 7.0. The mother liquor
was used for cryoprotection. Data collection was performed on the Northeastern
Collaborative Access Team beamline 24-ID-C at the Advanced Photon Source at
the iron peak. Data were indexed, integrated, and scaled using iMOSFLMand
Aimless. To avoid model bias molecular replacement was combined with
anomalous signals (MR-SAD) using Phaser and PDB 3REE as the search
model15. Refinement was performed using phenix27. Model building/rebuilding
was performed using Coot28. OMIT maps were constructed by removing the
ligand from the final refined structure file, performing three macro-cycles of
refinement with simulated annealing, and calculating a |Fo|—|Fc| map with
phenix.maps.
MitoNEET binding assay. Recombinant mitoNEET was attached to nickel




































































































Fig. 6 Mitochondrial effect of the compounds on murine neuronal N2A cells. The Seahorse Bio-analyzer was used to evaluate the effect of compounds on
mitochondrial function and bioenergetics in cells. Compounds were tested at 20 μM, with vehicle control treatment with DMSO only. Each bar represents
mean ± S.D. where N= 8. *Statistical significance P < 0.05
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rosiglitazone (PerkinElmer) for 60 min at room temperature. The binding
buffer was 50 mM Tris pH 8. White clear bottom 96-well plates were used
for the assay, and the counts per minute analyzed in a MicroBeta Counter
(Perkin Elmer). Data were analyzed as fraction of the total binding using a one-
site model with GrapPad Prism 6 statistical software. All binding curves had
R2 > 0.9.
Surface plasmon resonance. SPR studies were done by the contract research
organization CreativeBiolabs (https://www.creative-biolabs.com/). Experiments
were performed using Reichert4SPR refractometer system (Reichert Technolo-
gies, Depew, NY, USA) equipped with a dextran SPR sensor chip (Reichert
carboxymethyl dextran P/N 13206066). Acetate buffer was used for immobili-
zation of the protein MN (ligand). First, the surface was stabilized with phos-
phate buffer saline (PBST; PBS with 0.05% Tween 20, pH7.4) at a flow rate of 25
μL/min (25 °C) until a constant refractive index was obtained. Carboxymethyl
dextran on a chip was activated by injecting a solution of 10 mg/mL NHS and 40
mg/mL EDC over the sensor chip surface for 7 min at a flow rate of 10 μL/min.
Then the ligand, 60 μg/mL in 10 mM sodium acetate (pH 4.5), was immobilized
by injection over the surface for 7 min. The unreacted sites on the sensor chip
surface were blocked by injection of 1 M ethanolamine (pH 8.5) for 8 min. A
furosemide solution with 7 different concentrations (18.7, 25, 37.5, 50, 75,100,
and 150 μM) prepared in PBST (PBS with 0.05% Tween 20, pH7.4) with 1%
DMSO was injected into the cell over both channels at a flow of 25 μL/min,
association for 1.5 min, dissociation for 2.5 min. Data analysis were performed
with TraceDrawer software. Final Kd values were determined by fitting to a one-
to-one binding model.
Docking studies. The docking studies were performed using Glide (Schrodinger.
com). Our mitoNEET protein structure (6DE9) with furosemide was used in the
docking studies. The structure was prepared for docking using the PrepWizard that
added the necessary hydrogens. Glide SP docking was used in the default setting for
the docking studies of each compound. The top resultant poses were visually
inspected and the ligand interaction diagram function used to determine hydrogen
bonding. Pharmacophore features were identified from the docked poses and the
Pharmacophore editor in MOE 2018 (www.chemcomp.com). Final poses were
visualized in PyMol version 0.99.
Seahorse bioenergetics. Mitochondrial bioenergetics were evaluated by the use of
the Seahorse 96-well plate reader. Cells were grown in specialty plates from the
company, at 20,000 cells per well of N2A mouse neuronal cells. The cells were
treated with compounds at 20 μM for three hours, and then a mitochondrial stress
test (Seahorse Biosciences) done using compounds which affect mitochondrial
function, including oligomycin, FCCP, rotenone, and antimycin A.
Electron-transport chain complex activities. Electron-transport chain (ETC)
complexes I, III, IV, and V (ATP synthase) activities were measured spectro-
photometrically as previously described29. Briefly, brain and liver were resected
from mice. Mitochondria were isolated from organs using BioVision Mammalian
Mitochondria Isolation Kit for Tissue & Cultured Cells (Catalog #: K288), resus-
pended in 1 mL KME buffer each, and stored at −80 °C. Complex I activity was
determined by measuring NADH oxidation at 340 nm. Complex III activity was
assessed by measuring the reduction of cytochrome c at 550 nm in the presence of
reduced decycloubiquinone (50 μM). Complex IV activity was evaluated by mea-
suring the oxidation of cytochrome c at 550 nm. And ATP Synthase activity was
measured using an assay coupled with pyruvate kinase, which converts ADP to
ADP and produces pyruvate from phosphoenolpyruvate (PEP) measured at 340
nm. Each treatment group was comprised of 8 replicate wells in a 96-well plate.
Bradford assay was used to measure protein concentration in isolated mitochondria
from brain and liver that was used when performing calculations to obtain mea-
surements expressed as nanomoles substrate converted/min/mg of protein. The
mean measurement of each treatment group was compared with the mean of the
control group (DMSO only) with a one-way ANOVA using GraphPad Prism
8 software program following the exclusion of outliers as determined by the ROUT
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Fig. 7 Electron-transport complex activity of isolated murine brain mitochondria. Complex activity of isolated brain mitochondria were affected by
compounds. a Complex I; b Complex III; c Complex IV, and d ATP Synthase. Compounds were tested at 20 μM, with vehicle control treatment with DMSO
only Each bar represents mean ± S.D. where N= 6. Statistical significance *P < 0.05
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Dynamic light scattering. Compounds were dissolved in DMSO to give a 10 mM
stock concentration. This stock solution was diluted into PBS pH 7.4 to a final
concentration of 20 μM, and the evaluated using a Malvern DLS Nano-ZS-90
system (Malvern Instruments).
Iron–sulfur cluster release assay. This method was adapted as previously
described9. MitoNEET was prepared as described earlier and a stock of 4 mg/mL
was used in the assay, in a 50 mM Tris buffer pH 8. In a clear UV transparent 96-
well plate, compounds were prepared as 10 mM stocks in DMSO, and added to the
wells to give a final concentration of 20 μM. In each well 80 μL of the appropriate
buffer, with either vehicle or compound, and then mitoNEET protein was added at
20 μL. The 96-well plate was analyzed in a BioTek Synergy 4 plate reader, reading
at 458 nm for a period of time, at room temperature. For the pH 8, we used 50 mM
Tris pH 8, with 100 mM NaCl, and for the pH 6.5, we used the 50 mM Bis–Tris pH
6.5 with 100 mM NaCl buffer solution.
Capture assays. A biotin–furosemide probe was prepared by first activating the
carboxylic group of biotin with 1′-Carbonyldiimidazole (CDI) and conjugating it
with furosemide. For the ELISA assay, streptavidin plates (Pierce) were incubated
for 30 min with a dose-dilution of the probe, after which an equal amount of
recombinant mitoNEET protein was placed into the wells. After 2 h incubation at
4 °C, the plate was washed with a wash buffer with PBS pH 7.4 containing 0.05%
Tween-20. The amount of mitoNEET was determine using a mitoNEET primary
antibody (ProteinTech) 1:1000, followed by secondary anti-rabbit horseradish
peroxidase antibody 1:2000 for 1 h. Detection of the color was done at 450 nm after
addition of 3,3′,5,5′-tetramethylbenzidine solution and stopping solutions (Pierce).
For the capture assay, N2A cells were lysed and collected with radio-
immunoprecipitation assay buffer. Recombinant mitoNEET was added to the 1.5
ml centrifuge tubes, and magnetic streptavidin Dynanbeads (Invitrogen) incubated
with 100 μM furosemide probe was added to each tube. Furosemide, 0–100 μM was
added to tubes and incubated for 30 min. At the end of the experiment, a magnetic
tube rack was used to attract the magnetic beads. The solutions were washed with
PBST (pH 7.4, 0.05% Tween-20), boiled for 5 min, and run on a BioRad 4–20% gel
for Western Blot analysis (mitoNEET primary antibody 1:1000 and secondary HPR
1:2000).
Synthesis of furosemide analogs 2. A microwave vial containing 2,4-dichloro-5-
sulfamoylbenzoic acid (1, 0.74 mmol), Et3N (2.9 mmol) and primary amine (1.85
mmol) in 2 mL of DME was heated for 5 h at 150 °C under microwave irradiation.
The solution was cooled to room temperature, combined with EtOAc (30 mL) and
washed twice with equal volumes of 5% citric acid and brine. The organic fraction
was then dried over MgSO4, concentrated under reduced pressure, and loaded onto
a silica gel column packed with 1:1 hexanes:EtOAc. Flash chromatography using
50–100% EtOAc in hexanes yielded pure furosemide analogs 2 as pale solids.
Data availability
All data are available from the authors upon reasonable request. Coordinates and
structure factors were deposited in the Protein Data Bank under accession code 6DE9.
https://www.rcsb.org/.
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